Pharmacyclics — ASCO Investor Relations Presentation 2011
39 slides from Pharmacyclics's conference presentation, Jun 6, 2011
Slide 1: ASCO Investor Relations Presentation: BTK Inhibitor Program (PCI-32765)
ASCO Investor Relations Presentation: BTK INHIBITOR PROGRAM (PCI-32765) June 6, 2011 Presented by Eric Hedrick, MD Pharmacyclics, VP, Oncology Development Qaharmacyclics
Slide 2: Safe Harbor Statement
Safe Harbor Statement During the course of this presentation we will make statements that constitute forward-looking statements. These statements may include operating expense projections, the initiation, timing results of pending or future clinical trials, the actions or potential action of the FDA
Slide 3: CLL/SLL and Phase IA Summary Update
CLL/SLL and Phase IA Summary Update — Recap of ASCO Presentation Shown Earlier Today + Complete presentation is available on PCYC website — Phase IA Update — Q&A with Investigators * Dr.John Byrd, Ohio State University * Dr. Michael Wang, MD Anderson Btk Program Overview & Update @pharmac yclics
Slide 4: PCI-32765: Phase IB/II CLL Update
PCI-32765: Phase IB/II CLL Update The Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 is Highly Active and Tolerable in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Interim Results of an Ongoing Phase 1B/II Study Joun C. Byro, MD Kristié A. Blum, MD, JAN A. BUR
Slide 5: PCYC 1102: Phase IB/II Study Design
PCYC 1102: Phase IB/II Study Design Single-agent, multi-cohort study PCI-32765 in two subject populations with symptomatic CLL/SLL: — Treatment-naive, aged 2 65 years * Dose: 420 mg/day until progression (May 2010- March 2011) — Relapsed/Refractory (RR) * Dose #1: 420 mg/day until progression (May 2
Slide 6: Subject Characteristics
Subject Characteristics Treatment-Naive | Relapsed/Refractory | Relapsed/Refract« 420 mg/d (N=23) 420 mg/d (N=27) 840 mg/d (| 5) Age,y Median: 1 64 65 Range: 66-84 40-81 44-80 Dx, # pts CLL: 22 (96%) 26 (96%) 32 (97%) SLL: 1 (4%) 1 (4%) 1 (3%) Prior Rx, # Median: 0 3 5 Range: 2-10 2-12 Prior therapy
Slide 7: Subject Characteristics (cont.)
Subject Characteristics (cont.) Treatment- Relapsed/ Relapsed/ Naive Refractory Refractory 420 mg/d 420 mg/d 840 mg/d (N=23) (N=27) (N=33) Cytopenia at baseline, % ANC < 1500/UL 1 (4%) 6 (22%) 17 (52%) HGB < 1ig/db 7 (30%) 4 (15%) 19 (58%) Platelets < 100,000/uL 9 (39%) 8 (30%) 22 (67%) Prognostic M
Slide 8: Subject disposition: Treatment discontinuation
Subject disposition: Treatment discontinuation and disease progression have been uncom SUBJECT DISPOSITION Treatment- Relapsed/ | Relapsed/ Naive Refractory | Refractory 420 mg 420 mg 840 mg (N=23) (N=27) (N=33) Number of subjects 23 27 33 Follow-up Median (months) 63 78 4.6 Range 1.4-9.2 07-95 0.3-
Slide 9: Overview of Safety
Overview of Safety OVERVIEW OF SAFETY Relapsed/ Relapsed/ Refractory Refractory 420 mg (n=27) 840 mg (n=33) Deaths on study, # (%)! 0 (0%) 0 (0%) 2 (6%) Subjects with AE leading to discontinuation, # (%) 144) 1:(4%) 1%) Subjects with SAE, # (%) 4 (17%) 11(41%) 15 (46%) ~Related SAE, # (%) 0 (0%) 5 (
Slide 10: Pattern of response: Rapid lymph node reduction
Pattern of response: Rapid lymph node reduction, resolution of lymphocytosis over time TREATMENT- Naive PATIENTS © 200 400 600 % of Base SPD 00 05 1.0 15 © 50 100 150 200 250 300 © 50 10¢ 15¢ 200 25¢ 300 Time (Days) Time (Days) — © 50 100 150 200 250 300 © 50 10¢ 150 200 250 300 RELAPSED / REFRACTOR
Slide 11: CLL objective responses improve over time
CLL objective responses, per IWG criteri improve over time TREATMENT-NAIVE RELAPSED/REFRACTORY (420mg) (420mg) 70% 67% 70% > 60% a 60% 59% 50% 50% sae 2 | 2 41% 2 40% & 40% & 30% 24% 8 30% E 20% i a Z 20% -|19% 10% ‘a 10% | 0% | 0% Cycle2 Best Response Cycle 2 Best Response (n=21) (n=21) (n=27) (n=2
Slide 12: Response appears independent of high-risk genomic features
Response appears to be independent o risk genomic features RELAPSED/REFRACTORY PATIENTS: 420mcG CoHoRT Molecutar Riek Feature (Total coe peo Renae Overall 27 48% (13/27) 41% (11/27) Del17p 9 44% (4/9) 33% (3/9) Del11q 8 63% (5/8) 37% (3/8) igVH unmutated wv 53% (9/17) 29% (5/17) r 1 @pharmacyclics R
Slide 13: With longer follow-up, majority of patients remain progression-free
With longer follow-up, majority of patients remain progression-free beyond 6 mon TIME ON STUDY (420mG CoHortTs) il Naive(420mg) A | © ‘Treatment- = PO © sae "WC or|PI or Sponspr Decision Relapsed/Refractory (420me) 12 16 Time (months) 1R,6.6.2011 @pharmacyclics G20 RF) vs
Slide 14: Evolution of response data from Phase IA trial: May 2011 vs ASH 2010
Evolution of response data from Phase IA trial: May 2011 vs ASH 2010 PH IA RESPONSE DATA: PH IA RESPONSE DATA: ASH (Dec-2010) ASCO (Jun-2011) 100% 100% 7/9 ORR (Eval) 52% 1147/9 ORR (Eval) 62% 20% _ 8/9 _ 78% ORR(ITT) 45% 20% _ 79% 78% ORR(ITT) 55% x 69% x 2 60% 2 60% 3 g = 10% an A/33 = 40% 3 [| 31
Slide 15: Phase IA most common adverse events show no significant change
Phase IA most common adverse events show no significant change with longer follow-up hee ie Covgh TT Headache Nasco Muscle Spasms Myalgia Oedema Peripheral Pyrexia Abdominal Pain Constipation Anemia Arthralgia Back Pain Vomiting 0% 20% 40% 60% 80% 100% mGrade1 _mGrade2mGrade3 6/2001 14:5853 An Qphar
Slide 16: Phase IA: patients remain on treatment to date
Phase IA: 22 patients remain on treatment to date a = ro) re) = a 3 a s a —————————— B Onstudy z PO Qe ma © WCor PI Decision BSz Bow io B82 8 15 20 25 10 Time (months) Qaharmacye ics
Slide 17: Investigator Q&A
INVESTIGATOR Q&A Dr. John Byrd, Ohio State University Dr. Michael Wang, MD Anderson IR rn Qaharmacyclics
Slide 18: Agenda
Agenda CLL/SLL Summary Update Btk Program Overview & Update — Clinical Overview * Trial Overview * Details by Histology * Near-Term Trial Overview — Commercial Overview f @pharmacyclics ‘ RF) ys
Slide 19: Enrollment to PCI-32765 trials has been robust
Enrollment to PCI-32765 trials has been robust OVERALL PATIENT ENROLLMENT FOR PCI-32765 1 1106-DLBCL Monotherapy 200 [21104 MCL Monotherapy 1109-CLL Combo w/Ofa 1 1108-CLL Combo w/ BR or FCR | 1§1102-CLL Monotherapy 1§4753-8-Cell Malignancies 100 50 0 saad Accumulative Enrollment in PCI-32765 Btk St
Slide 20: Phase II program is progressing well
Phase II program is progressing well ENROLLMENT PERIODS & STATUS, ACTIVE PCI-32765 TRIALS CURRENT Relapsed// Refractory Trials: STATUS [roi scunnsionances | [EEA erate no a amy Phill Compo with FCR and Be a Envtted fecnai A) CES mee ofa slant Enrolled aie Pa a ea reo are one pain nae wee May coll Pa
Slide 21: Current Status
Current Status Phase IB/II interim results * Confirm high level of activity of PCI-32765 in treatment-naive andrelapsed/ refractory patients Favorable safety profile allowing prolonged dosing (CURRENT DATA Phase IB combination safety trials (Ofatumumbab, BR) are UPCOMING enrolling well, 3-month safe
Slide 22: Current Status: MCL
Current Status High response rate observed in Phase IA trial fetta ia) Vwae ° Longer follow-up of that trial suggests responses can be durable MCLPh Il single agent trial in relapsed/ refractory (bortezomib- naive and bortezomib-exposed) patients ongoing + 30/100 already enrolled in 3+ months = Prel
Slide 23: DLBCL: Current Status
DLBCL: Current Status * Objective responses observed in phase | trial, but activity in ABC CURRENT DATA DLBCL not assessed Pilottrial in ABC DLBCL ongoing at NCI, 8/10 patients enrolled UpcomiNG Anticipate pilot data to be reported at ASH 2011 Data Phase Il single-agent trial in relapsed/ refractory
Slide 24: NCI pilot study in RR ABC DLBCL
NCI pilot study in RR ABC DLBCL designed to explore PCI-32765 in BCR pathway — National Cancer Institute, Clinical Center — Wyndham Wilson, MD (Principal Investigator) Current Enrollment: — 8/10 Objective: — Assess response rate and correlate response with target gene expression (BCR pathway) — Prel
Slide 25: Profile of one NCI ABC DLBCL patient in complete remission
Profile of one NCI ABC DLBCL pa complete remission PATIENT: 48 year old male PRIOR THERAPIES: Aug 2007: Rituximab => R-CHOP x 6 Dec 2008: R-ESHAP => Autologous bone marrow transplant Sept 2009: Orchiectomy and testicular radiation June 2010: Ocular radiation July 2010: Retrocardiac radiation Dec 201
Slide 26: PET/CT scan of one NCI ABC DLBCL patient
by Histology PET/CT scan of one NCI ABC DLBC with complete remission — BEFORE RX ON Rx: WEEK 10
Slide 27: Follicular: Current Status
Follicular: Current Status * From Phase IA trial, overall response rate in FL has improved, CURRENT DATA with late conversions to CR observed Uncomue * Phase Il combination trial planned Data EGE «Late (Phase Ill) development dependent on combinability with chemotherapy and activity in rituximab-ref
Slide 28: Multiple Myeloma: PC and Clinical Overview
Multiple Myeloma: PC and Clinical Overview Ti i + Not applicable OTHER + Pre-clinical results are encouraging (Details in following slides) On-GoING + Company evaluating MM clinical trial strategy ACTIVITIES TARGETED * * Initiate Phase I/II single agent trial in Q4 2011 NEAR-TERM MILESTONES * These
Slide 29: Rationale for PCI-32765 in Multiple Myeloma
Rationale for PCI-32765 in Multiple Myeloma * Btkis essential for myeloma-driven bone degradation — PCI-32765 inhibits osteoclast development and function stimulated by myeloma * Btkis frequently expressed in myeloma patient samples and in putative stem cells — PCI-32765 inhibits myeloma colony form
Slide 30: Clinical trial expansion in near-term
Clinical trial expansion in near-term Trial (All Relapsed Refractory) Phase IB in MCL Combination Phase 1B in DLBCL Combination Phase I! in FollicularLymphoma Combination Phase I/Il in Multiple Myeloma Note: These are current corporate estimates and may vary depending on future circumstances, Qaharm
Slide 31: Development to date is on schedule
Development to date is on schedule, furthers goal to maximize patient benefit PCI-32765 DEVELOPMENT SUCCESS-TO-DATE — Successful execution of clinical development plan as outlined at ASH 2010 — Ongoing trials have confirmed that PCI-32765 is highly active as a single agent in CLL and MCL — Upcoming
Slide 32: Agenda
Agenda CLL/SLL Summary Update Btk Program (PCI-32765) Overview & Update — Clinical Overview — Commercial Overview R @pharmacyclics ‘ RF) ys
Slide 33: PCI-32765 demonstrates attributes of an important drug in B-cell malignancies
PCI-32765 demonstrates attributes of an important drug in B-cell malignancies — Highly active as single agent +++ * Established in four key NHL histologies — Combines safely and effectively + * Initial proof targeted late 2011 — Lowtoxicity +++ * Established with no significant concerns to-date — Po
Slide 34: Rituxan's success based on high efficacy and low toxicity
Rituxan’s success based on high efficacy ; low toxicity in unmet needs RITUXAN SALES, WW, 1997-2015e 2010(€U),2011(US): line FL maintenance2014 & 2015: Setoom 2009(EU),2010(US): patent expiration $7,000 Aline & rel/ref CLL, combow/FC $ $6,000M 2006(US, EU), 3 Ptine in RA —$5,000M 3 2004(€U),2006(U5)
Slide 35: Gleevec shifted an acute disease to chronic
Gleevec shifted an acute disease to chro GLEEVEC SALES, WW, 1997-2017e $6,000M $5,000M $4,000M $3,000M $2,000M $1,000M | | som -= 2 es 888 Source: Novartis ond Credit Suisse Worldwide Sales 200. a 2004 = 2001 2003 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 R A @pharmacyclics 4 RF) ys
Slide 36: G7 Pharmacyclics Targeted Patients
(G7 Pharamacyces Targeed Patients G7 NHL DIAGNOSED TREATABLE PATIENTS, 2011 60,000 Japan 0,000 sEUS mus 40,000 | 30,000 20,000 — = cL CLL SLL. DLeCL Follicular RR Fronline& | RR Frontine&| RR —Frontine&| RR Frontine & Maintenance Mantenance Maintenance Martenance ‘Source: Decision Resources, 2011 No
Slide 37: G7 NHL market value projected to grow
G7 NHL market value projected to grow from $5.0B today to $8.4B in 2019e NHL SALEs, WW, 2010 vs 2019e $10.08 $10.08 $9.08 | $9.08 $8.08 ~ $8.08 $7.08 + $7.08 $6.08 | $6.0B ~ $5.08 $5.08 $4.08 - $4.08 $3.0B + $3.0B ~ $2.08 + $2.08 ~ $1.08 | $1.08 $0.08 + 1 $0.08 + 2010 2019 Source: Decision Resources
Slide 38: Btk program has multi-billion dollar potential
Btk program has multi-billion dollar potential Patient Benefit Assuming continued clit US and worldwide regul approvals, Pharmacycl ics € PCI-32765 to have annua multi: billion dollar revent RETREATMENT. MaiNTENANCE FRONT LINE RELAPSED / REFRACTORY > Single Agent >>> and/or >>> Combination Qaharmacy
Slide 39: ASCO Investor Relations Presentation: BTK Inhibitor Program (PCI-32765)
ASCO Investor Relations Presentation: BTK INHIBITOR PROGRAM (PCI-32765) June 6, 2011 Presented by Eric Hedrick, MD Pharmacyclics, VP, Oncology Development Qaharmacyclics
Pharmacyclics — ASCO Investor Relations Presentation 2011 on 6ix